Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Newcastle disease virus (NDV), also known as avian paramyxovirus type 1 (APMV-1), is a single-stranded negative-sense RNA virus in the family Paramyxoviridae. It is the causative agent of Newcastle disease—a highly contagious and often severe viral infection affecting birds worldwide. NDV exists in three main pathotypes based on virulence in chickens: lentogenic (mild), mesogenic (moderate), and velogenic (highly virulent). Velogenic strains are responsible for major outbreaks with high mortality rates in poultry[1][2][4]. Lentogenic strains are widely used as live vaccines to prevent Newcastle disease[6][7]. The primary mechanism of action for vaccine use is induction of protective immunity against NDV through exposure to attenuated or inactivated viral antigens. In research settings and experimental cancer therapy contexts, NDV has been explored as an oncolytic agent due to its ability to selectively replicate in and kill certain tumor cells while sparing normal tissues[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on newcastle disease virus.